Results 151 to 160 of about 3,003 (174)
Some of the next articles are maybe not open access.
The American Journal of Cardiology, 1995
Abstract This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 ma/kg/hour over 48 hours ...
Uwe Zeymer +6 more
openaire +1 more source
Abstract This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 ma/kg/hour over 48 hours ...
Uwe Zeymer +6 more
openaire +1 more source
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2018
To investigate the effect of natural hirudin combined with hyperbaric oxygen therapy on the survival of transplanted random-pattern skin flap in rats.A random-pattern skin flap in size of 10.0 cm×2.5 cm was elevated on the dorsum of 72 Sprague Dawley rats. Then the 72 rats were randomly divided into 4 groups ( n=18) according to the therapy method.
Jieyun, Cai +5 more
openaire +1 more source
To investigate the effect of natural hirudin combined with hyperbaric oxygen therapy on the survival of transplanted random-pattern skin flap in rats.A random-pattern skin flap in size of 10.0 cm×2.5 cm was elevated on the dorsum of 72 Sprague Dawley rats. Then the 72 rats were randomly divided into 4 groups ( n=18) according to the therapy method.
Jieyun, Cai +5 more
openaire +1 more source
Herz, 1999
Plaque rupture with consecutive formation of an intraluminal, platelet-rich thrombus is the central mechanism leading to critical reduction of coronary perfusion in the acute coronary syndrome. Current therapeutic strategies aim at the inhibition of activation of platelets and the coagulation cascade and the suppression of platelet aggregation and ...
A, Gaede, W, Terres
openaire +1 more source
Plaque rupture with consecutive formation of an intraluminal, platelet-rich thrombus is the central mechanism leading to critical reduction of coronary perfusion in the acute coronary syndrome. Current therapeutic strategies aim at the inhibition of activation of platelets and the coagulation cascade and the suppression of platelet aggregation and ...
A, Gaede, W, Terres
openaire +1 more source
Journal of the American College of Cardiology, 1998
This study assessed the prognostic impact of right ventricular involvement (RVI) in streptokinase-treated patients with inferior acute myocardial infarction (AMI) stratified for small or large AMI.Only scant data exist from small studies about the impact of reperfusion therapy on survival in patients with RVI during inferior AMI.Right ventricular ...
U, Zeymer +5 more
openaire +1 more source
This study assessed the prognostic impact of right ventricular involvement (RVI) in streptokinase-treated patients with inferior acute myocardial infarction (AMI) stratified for small or large AMI.Only scant data exist from small studies about the impact of reperfusion therapy on survival in patients with RVI during inferior AMI.Right ventricular ...
U, Zeymer +5 more
openaire +1 more source
The American journal of cardiology, 1995
This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 mg/kg/hour over 48 hours).
U, Zeymer +6 more
openaire +1 more source
This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 mg/kg/hour over 48 hours).
U, Zeymer +6 more
openaire +1 more source
Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis
American Journal of Hematology, 1993openaire +2 more sources
Management of HIT II Patients with Hirudin Antibodies after Primary Therapy
ains · Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie, 2002openaire +2 more sources
Determination of specific activity of recombinant hirudin using a thrombin titration method
Thrombosis Research, 1995Lalitha Iyer
exaly
A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition
Journal of Thrombosis and Thrombolysis, 2008Wei Mo, Zhang Yan-Ling
exaly